paclitaxel and vx680
paclitaxel has been researched along with vx680 in 5 studies
Research
Studies (5)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Morioka, M | 1 |
| Benigno, BB; Laycock, N; Logani, S; McDonald, JF; Moreno, CS; Osunkoya, AO; Scharer, CD | 1 |
| Bak, A; Bush, TL; Cee, VJ; Chung, G; Deak, HL; Dussault, I; Eden, P; Geuns-Meyer, S; Hodous, BL; Kendall, RL; McElroy, P; Nguyen, HN; Olivieri, PR; Patel, VF; Payton, M; Radinsky, R; Romero, K; Ross, S; Schenkel, LB; Stanton, M; Ziegler, B | 1 |
| Deng, X; Gray, N; Huang, HC; Kwiatkowski, N; Mitchison, T; Musacchio, A; Santaguida, S; Tan, L; Villa, F; Wang, J | 1 |
| Huang, D; Murray, GF; Reed, J; Roy, IJ; Teitell, MA; Zangle, TA | 1 |
Other Studies
5 other study(ies) available for paclitaxel and vx680
| Article | Year |
|---|---|
3-Cyano-6-(5-methyl-3-pyrazoloamino) pyridines (Part 2): A dual inhibitor of Aurora kinase and tubulin polymerization.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Aurora Kinases; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; Mice; Molecular Structure; Neoplasms, Experimental; Polymerization; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship; Tubulin | 2016 |
Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells.
Topics: Aged; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Aurora Kinases; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Female; Gene Expression Profiling; Humans; Middle Aged; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Piperazines; Protein Serine-Threonine Kinases | 2008 |
Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
Topics: Adult; Animals; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Benzamides; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; HCT116 Cells; HeLa Cells; Histones; Humans; Mice; Mice, Nude; Mutation; Neoplasms; Organophosphates; Paclitaxel; Phosphorylation; Phthalazines; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase B; Aurora Kinases; Benzazepines; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; Isoenzymes; M Phase Cell Cycle Checkpoints; Models, Molecular; Organophosphates; Paclitaxel; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Quinazolines; Structure-Activity Relationship; Xenopus laevis | 2012 |
Identifying fates of cancer cells exposed to mitotic inhibitors by quantitative phase imaging.
Topics: Antineoplastic Agents; Aurora Kinase A; Cell Line, Tumor; Colchicine; Humans; Mitosis; Paclitaxel; Piperazines; Proof of Concept Study; Protein Kinase Inhibitors; Tubulin Modulators | 2019 |